MedPath

Efficacy of sitafloxacin as third-line eradication treatment of Helicobacter pylori

Phase 2
Conditions
H. pylori infection
Registration Number
JPRN-UMIN000004778
Lead Sponsor
ational Organization Tokyo medical center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patient with severe heart failure, renal failure or infection. 2. Patients with allergy for rabeprazole, amoxicillin or sitafloxacin. 3. Pregnant patient.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Eradication rate
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath